Trang chủ › Bạch cầu tủy cấp › Massachusetts › Boston
Thử nghiệm lâm sàng cho Bạch cầu tủy cấp tại Boston, MA
44 nghiên cứu cho Bạch cầu tủy cấp đang tìm kiếm người tham gia tại các cơ sở ở Boston và vùng lân cận (bán kính khoảng 30 dặm). Mở nghiên cứu để xem tiêu chí tham gia và cách liên hệ với đội ngũ nghiên cứu.
Văn bản nghiên cứu chính thức (Tiếng Anh)
Đang tuyển dụng cho một nghiên cứu? Đưa tin của bạn lên đầu trang này — $99 trong 30 ngày →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Đang tuyểnGiai đoạn 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ivosidenib as Post-HSCT Maintenance for AML
Đang tuyểnGiai đoạn 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Đang tuyểnGiai đoạn 1
- Dana-Farber Cancer Institute, Boston
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Đang tuyểnGiai đoạn 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Đang tuyểnGiai đoạn 3
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Đang tuyểnGiai đoạn 2
- Tufts Medical Center, Boston
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Đang tuyểnGiai đoạn 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Đang tuyểnGiai đoạn 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Đang tuyểnGiai đoạn 1/2
- Dana-Farber Cancer Center, Boston
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Đang tuyểnGiai đoạn 3
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Đang tuyểnGiai đoạn 2
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Đang tuyểnGiai đoạn 1/2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Đang tuyểnGiai đoạn 1/2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
Đang tuyểnGiai đoạn 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Đang tuyểnGiai đoạn 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Đang tuyểnGiai đoạn 1
- Dana-Farber Cancer Institute, Boston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Đang tuyểnGiai đoạn 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Đang tuyểnGiai đoạn 1
- Dana-Farber Cancer Institute, Boston
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Đang tuyểnGiai đoạn 3
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Đang tuyểnGiai đoạn 1
- Beth Israel Deaconess Medical Center, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Đang tuyểnGiai đoạn 1Chào đón tình nguyện viên khỏe mạnh
- Brigham and Women's Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Đang tuyểnNghiên cứu quan sát
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Đang tuyểnGiai đoạn 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Đang tuyểnGiai đoạn 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Đang tuyểnGiai đoạn 1
- Dana Farber Cancer Institute, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Đang tuyểnNghiên cứu quan sát
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Đang tuyểnGiai đoạn 1
- Dana Farber Cancer Institute, Boston
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Đang tuyểnGiai đoạn 1
- Beth Israel Deaconess Medical Center, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Đang tuyểnGiai đoạn 2/3
- Dana-Farber Cancer Institute, Boston
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Đang tuyểnGiai đoạn 2
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
Đang tuyểnGiai đoạn 1
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Đang tuyểnGiai đoạn 1/2
- Massachusetts General Hospital, Boston
Ziftomenib Maintenance Post Allo-HCT
Đang tuyểnGiai đoạn 1
- Massachusetts General Hospital, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Đang tuyểnGiai đoạn 2
- Dana-Farber Cancer Institute, Boston
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Đang tuyểnGiai đoạn 1
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Đang tuyểnGiai đoạn 1
- Massachusetts General Hospital, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Đang tuyểnGiai đoạn 2Chào đón tình nguyện viên khỏe mạnh
- DFCI/BWH Brigham and Women's Hospital, Boston
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Đang tuyểnGiai đoạn 1
- DFCI, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Đang tuyểnGiai đoạn 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Novel Digital Application for Patients With Acute Leukemia
Đang tuyển
- Massachusetts General Hospital (MGH), Boston
IS-free Treg HaploHCT
Đang tuyểnGiai đoạn 1
- Dana Farber Cancer Institute, Boston
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Đang tuyểnChào đón tình nguyện viên khỏe mạnh
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Đang tuyểnGiai đoạn 1
- Dana Farber Cancer Institute, Boston
Study of REM-422 in Patients With AML or Higher Risk MDS
Đang tuyểnGiai đoạn 1
- Massachusetts General Hospital, Boston
Thử nghiệm cho Bạch cầu tủy cấp tại các thành phố khác
- Houston, TX85 nghiên cứu
- New York City, NY51 nghiên cứu
- Seattle, WA41 nghiên cứu
- Baldwin Park, CA40 nghiên cứu
- Columbus, OH35 nghiên cứu
- Philadelphia, PA34 nghiên cứu
- Durham, NC33 nghiên cứu
- Atlanta, GA31 nghiên cứu
- Tampa, FL29 nghiên cứu
- Chicago, IL26 nghiên cứu
- Portland, OR25 nghiên cứu
- Washington, DC24 nghiên cứu
Các nghiên cứu khác tại Boston
- Ung thư vú112 nghiên cứu
- Ung thư phổi không tế bào nhỏ90 nghiên cứu
- Ung thư (mọi loại)85 nghiên cứu
- Ung thư di căn63 nghiên cứu
- Ung thư đại trực tràng63 nghiên cứu
- Ung thư phổi62 nghiên cứu
- Ung thư buồng trứng61 nghiên cứu
- Ung thư tuyến tiền liệt59 nghiên cứu
- Trầm cảm52 nghiên cứu
- Ung thư nội mạc tử cung50 nghiên cứu
- Suy tim44 nghiên cứu
- Ung thư tụy43 nghiên cứu
Nguồn dữ liệu từ ClinicalTrials.gov, cập nhật ngày 6 thg 10, 2026. Mỗi nghiên cứu có tiêu chí riêng; đội ngũ nghiên cứu sẽ quyết định ai đủ điều kiện tham gia.